143TiP MountainTAP-29: A randomized phase II/III study of first-line (1L) BMS-986504 + pembrolizumab (pembro) + chemotherapy (chemo) in patients (pts) with metastatic NSCLC with homozygous MTAP deletion (MTAP-del)